@Locked I didn't release that MSB licenced JCR as a result of a patent breach. The MSCs they are using are expanded from bone marrow (same technology largely as what we are using). Cynata uses induced pluripotent stem cells. I suspect, as they are manufactured using a different source and different technology that they might not breach our patents. In early days there was concern about pluripotent cells being able to differentiate into cancers etc. unlike our MSCs that are unable to differentiate further.
Pluristem use stem cells that are further up the chain and struggle with higher doses and perhaps less effectiveness.
Cynata claiming their cells far superior to MSB's, page-7
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.015(1.49%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | 99.5¢ | $2.005M | 1.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14424 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 63643 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |